Downloads: 61

Files in This Item:
File Description SizeFormat 
j.vhri.2021.07.011.pdf1.82 MBAdobe PDFView/Open
Title: Cost Analysis of Screening for IgA Nephropathy Using Novel Biomarkers
Authors: Ishida, Mami
Matsuzaki, Keiichi
Ikai, Hiroshi
Suzuki, Hitoshi
Kawamura, Takashi
Suzuki, Yusuke
Author's alias: 石田, 真美
松崎, 慶一
川村, 孝
Keywords: cost analysis
cost-effectiveness
IgA nephropathy
novel biomarkers
screening
chronic kidney disease
end-stage kidney disease
Issue Date: May-2022
Publisher: Elsevier BV
Journal title: Value in Health Regional Issues
Volume: 29
Start page: 8
End page: 15
Abstract: [Objectives] IgA nephropathy (IgAN) is the most common primary chronic glomerulonephritis and a major cause of end-stage kidney disease worldwide. Novel biomarkers, including the aberrantly glycosylated IgA1 and glycan-specific antibodies, could be useful in the diagnosis of IgAN. The aim of this study was to assess the cost analysis of IgAN screening using novel biomarkers in addition to the conventional screening compared with conventional screening alone. [Methods] To estimate the medical expense of each strategy related to renal disease for 40 years, we developed an analytical decision model. The decision tree started at “40 years of age with first-time hematuria.” It simulated 2 clinical strategies: IgAN screening using the novel biomarkers (group N) and conventional screening (group C). The analysis results were presented as medical expenses from a societal perspective. Discounting was not conducted. [Results] The expected medical expense per person for 40 years was ¥31.2 million (~$291 000) in group N and ¥33.4 million (~$312 000) in group C; hence, expense in group N was lower by ¥2.2 million (~$21 000). In group N, the expected value of IgAN increased by 5.67% points (N 48.44%, C 42.77%) and that of dialysis introduction decreased by 0.85% points (N 19.06%, C 19.91%). In the sensitivity analysis, expenses could be reduced in almost all cases except when renal biopsy using conventional screening was performed at the rate of 73% or higher. [Conclusion] Screening for IgAN using novel biomarkers would reduce renal disease–related expenses.
Rights: © 2021 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.
This is an open access article under the CC BY license.
URI: http://hdl.handle.net/2433/281698
DOI(Published Version): 10.1016/j.vhri.2021.07.011
PubMed ID: 34794047
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons